Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 9/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | TP53 | P04637 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21623378 | 1.00 | CYP1A2 (0.48) | CYP1A2HTR2BFEN1ALOX5APMAPT | |
| SCHEMBL21623241 | 1.00 | CYP1A2 (0.48) | CYP1A2HTR2BFEN1ALOX5APMAPT | |
| SCHEMBL21623257 | 0.90 | MAPT (0.47) | CYP1A2HTR2BMAPTTP53LMNA | |
| SCHEMBL21623254 | 0.90 | MAPT (0.47) | CYP1A2HTR2BMAPTTP53LMNA | |
| SCHEMBL21623326 | 0.90 | MAPT (0.47) | CYP1A2HTR2BMAPTTP53LMNA | |
| SCHEMBL21623558 | 0.85 | CYP1A2 (0.69) | CYP1A2FEN1ALOX5APCYP3A4CYP2D6 | |
| SCHEMBL21623566 | 0.85 | CYP1A2 (0.69) | CYP1A2FEN1ALOX5APCYP3A4CYP2D6 | |
| SCHEMBL21623560 | 0.85 | CYP1A2 (0.69) | CYP1A2FEN1ALOX5APCYP3A4CYP2D6 | |
| SCHEMBL21623120 | 0.83 | CYP1A2 (0.55) | CYP1A2MAPTTP53LMNACYP3A4 | |
| SCHEMBL21623574 | 0.83 | CYP1A2 (0.45) | CYP1A2HTR2BFEN1ALOX5APMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | claimed |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| CN-112912368-A | Inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3823957-A1 | INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016427-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016427-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, HDGF | CYP1A2 1300/4885HTR2B 4406/4885FEN1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.